Quantcast

Industry news that matters to you.  Learn more

Mayo Clinic Hosts NIH Genomics Director at Individualizing Medicine Conference

From Promise to Practice is the title and the main message of the second annual Individualizing Medicine Conference at Mayo Clinic, Sept. 30-Oct. 2. Physicians from more than 40 states and several countries will be arriving in Minnesota to hear and learn about the latest developments and research in genomic research and how to move these discoveries into the medical practice. “Our goal is to inform practicing physicians, but other care providers, students, media and the public as well,” says Richard Weinshilboum, M.D., chair of this year’s conference held by Mayo Clinic’s Center for Individualized Medicine. “Individualizing prevention, diagnosis and treatment is the core of medical genomics and the future of medicine. Even if you missed the last 13 years since the mapping of the human genome, we’ll help you catch up in three days.”

Opening keynote speaker on Monday, September 30, will be Eric Green, M.D., Ph.D., director of the National Institute of Genomic Health Research, Bethesda, M.D. Co-hosts for the conference will be Richard Besser, M.D., chief health and medical editor for ABC News and former acting director of the Centers for Disease Control, and Ceci Connolly, managing director of the Health Research Institute, PwC.

The conference offers expert speakers, focused breakout sessions, and real-life case studies so participants can discover and discuss emerging topics in medical genomics. Topics range from translating genomic findings into clinical care to communicating accurately and ethically with patients. Also this year, on Sunday, Sept. 29, an “Omics 101” seminar will be offered at a lay level for those new to individualized medicine. This course is being offered separately and is ideal for students and media who will be working in or reporting on the genomics field.

Individualized medicine is a growing field of patient care based on the increasing knowledge of the human genome, mapped just a decade ago. Mayo Clinic is a leader in transferring medical genomics to medical practice clinomics as evidenced by its Individualized Medicine Clinic, launched a year ago. Mayo’s Center for Individualized Medicine also includes programs in biomarker discovery, pharmacogenomics, epigenomics and the human microbiome.

Source: Mayo Clinic

Epigenomics AG Announces Non-exclusive Licensing Agreement for Septin9 with Companion Dx Reference Lab

Epigenomics AG (Frankfurt Prime Standard: ECX), the German-American cancer molecular diagnostics company, announced today that it signed a non-exclusive licensing agreement for its proprietary DNA methylation biomarker Septin9 with Companion Dx Reference Lab (“Companion Dx”), an emerging leader in pharmacogenomic testing and cancer companion diagnostics. Under the terms of the agreement, Companion Dx has obtained rights to establish and commercialize a blood-based, laboratory-developed test (LDT) using methylated Septin9 as biomarker for the detection of colorectal cancer. Epigenomics is entitled to double digit royalties on sales.

“The addition of Septin9 to our offering of cancer related products will allow us to more effectively serve the Texas cancer testing market. Colorectal cancer is the second leading cause of cancer-related deaths in the U.S., and we believe that the blood based method to detect colorectal cancer in the currently non-compliant patient population will improve participation in screening and therefore save more lives in Texas”, said Steve Blum, CEO of Companion Dx.

“Based on the growing uptake of the Septin9 assay through our LDT licensees, we are excited to add regionally focused Companion Dx lab to the list of our partners as we recognize their ability to reach incremental sub-populations who should be but are not currently screened according to guidelines”, said Noel Doheny, Chief Executive Officer of Epigenomics’ US subsidiary. “Companion Dx shares our objective of providing tests that will help physicians to improve the health outcomes for patients through accurate detection of colorectal cancer and to potentially decrease the rising costs associated with colorectal cancer in the U.S. With today’s licensing agreement, we continue to execute on our commercialization strategy, well ahead of the launch of a proprietary diagnostic product approved by the FDA”, explained Mr. Doheny.

The agreement with Companion Dx complements Epigenomics’ LDT agreements with Quest Diagnostics, ARUP Laboratories and Warnex Medical Laboratories in North America. Furthermore, Abbott Molecular has worldwide, non-exclusive license to develop and to commercialize IVD test kit products while Qiagen and Sysmex have acquired options to do so.

Source:

Epigenomics Septin9 Biomarker Detects Colon Cancer Equally in Both Sides of the Colon

Epigenomics AG, the German-American cancer molecular diagnostics company, is pleased to announce the results from a study conducted in collaboration with Professor Dr. Béla Molnár and his team from the 2nd Department of Internal Medicine of Semmelweis University in Budapest, Hungary. In the study, the blood based detection of methylated Septin9 in colorectal cancer (CRC) cases was assessed in the left and right side of the colon.

Epigenomics Biomarker Predicts Drug Resistance in Colorectal Cancer

Epigenomics AG, the German-American cancer molecular diagnostics company, is pleased to announce the publication of a study authored by Professor Matthias Ebert at University of Heidelberg entitled “TFAP2E-DKK4 and Chemoresistance in Colorectal Cancer” in the January edition of The New England Journal of Medicine.

Epigenomics and QIAGEN Sign Collaboration Agreement in Colorectal Cancer Blood Testing

Epigenomics AG and Qiagen announced yesterday that they have entered into an option agreement allowing Qiagen to develop and, should Qiagen exercise the option, commercialize a colorectal cancer blood test based on Epigenomics’ proprietary biomarker mSEPT9 and certain DNA methylation analysis technologies.